OKYO
OKYO Pharma LimitedNASDAQHealthcare$1.68-6.55%ClosedMarket Cap: $64.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-17.20
P/S
0.00
EV/EBITDA
-5.86
DCF Value
$-0.11
FCF Yield
-5.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
102.9%
ROA
-99.3%
ROIC
154.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | -Infinity% | $-2.8M | $-2.6M | $-0.07 | — |
| Q4 2025 | $0.00 | -Infinity% | $-4.2M | $-2.0M | $-0.04 | — |
| FY 2025 | $0.00 | -Infinity% | $-7.2M | $-4.7M | $-0.12 | — |
| Q2 2025 | $0.00 | -Infinity% | $-3.0M | $-2.7M | $-0.08 | — |
| Q4 2024 | $0.00 | -Infinity% | $-7.0K | $-8.0K | $-0.24 | — |
| FY 2024 | $0.00 | -Infinity% | $-15.7M | $-16.8M | $-0.00 | — |
| Q2 2024 | $0.00 | -Infinity% | $-8.7K | $-8.8K | $-0.00 | — |
| Q4 2023 | $0.00 | -Infinity% | $-7.7K | $-7.8K | $-0.00 | — |
| FY 2023 | $0.00 | -Infinity% | $-13.1M | $-13.3M | $-0.60 | — |
| Q2 2023 | $0.00 | -Infinity% | $-4.6K | $-4.6K | $-0.00 | — |
| Q4 2022 | $0.00 | -Infinity% | $-6.9M | $-5.8M | $-0.36 | — |
| FY 2022 | $0.00 | -Infinity% | $-6.2M | $-5.4M | $-0.36 | — |